Nogapendekin alfa inbakicept

Phase 2Protein / enzyme

IImmunityBio, Inc.

Nogapendekin alfa inbakicept is one of 112 small molecule programs targeting Pneumonia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

111

Competitors

Pipeline

Status by Indication[3][1]

Indication

PneumoniaActive, not recruiting

LymphopeniaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Non-Small Cell Lung Cancer Stage IVNot yet recruiting

Synovial SarcomaActive, not recruiting

PneumoniaPhase 2

Active, not recruiting

LymphopeniaPreclinical

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Pancreatic CancerPhase 1

Active, not recruiting

Non-Small Cell Lung Cancer Stage IVPreclinical

Not yet recruiting

Synovial SarcomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Nogapendekin alfa inbakicept

IImmunityBio, Inc.

Phase 2

7 2

Lenvima

Eisai

Preclinical

6 3

Imjudo

AstraZeneca

Preclinical

5 4

Vizimpro

Pfizer

Preclinical

4 5

Gilotrif

Boehringer Ingelheim

Preclinical

12 6

Ofev

Boehringer Ingelheim

Preclinical

7 7

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 8

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 9

Treatment

GSK

Preclinical

1 10

Immune Checkpoint Inhibitor

IImmuneSensor Therapeutics Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Not yet recruiting

Pneumonia

NCT07492888

Q2 2029

Phase 1Not yet recruiting

Pancreatic Cancer

NCT07488884

Q4 2029

Phase 3Not yet recruiting

Pneumonia

NCT07492875

Q3 2032

PreclinicalRecruiting

Non-Small Cell Lung Cancer Stage IV

NCT07355205

Phase 1Not yet recruiting

Synovial Sarcoma

NCT07261657

Clinical

Trials by Indication[1]

Pneumonia2 trials

Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia

Not yet recruiting·IImmunityBio, Inc.·Phase 3·NCT07492875·10 enrolled

Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)

Not yet recruiting·IImmunityBio, Inc.·Phase 2·NCT07492888·20 enrolled

Urothelial Cancer1 trial

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

Withdrawn·VVadim S Koshkin·Phase 1·NCT07217496

Pancreatic Cancer1 trial

Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer

Not yet recruiting·IImmunityBio, Inc.·Phase 1·NCT07488884·30 enrolled

Synovial Sarcoma1 trial

N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy

Not yet recruiting·NNorthwestern University·Phase 1·NCT07261657·8 enrolled

Lymphopenia1 trial

Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Immunotherapy, and/or Radiation Therapy

Available·IImmunityBio, Inc.··NCT06956547

1 more indication

Non-small Cell Lung Cancer Stage IV1 trial

A Phase Ib/II, Single-Center, Open-Label Study of First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (FLINN)

Recruiting·WWashington University School of Medicine·Preclinical·NCT07355205·26 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Nogapendekin alfa inbakicept. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nogapendekin alfa inbakicept compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nogapendekin alfa inbakicept. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ImmunityBio, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 2[1]
Company: IImmunityBio, Inc.

Nogapendekin alfa inbakicept

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2029

Q4 2029

Q3 2032

Trials by Indication[1]

Pneumonia2 trials

Urothelial Cancer1 trial

Pancreatic Cancer1 trial

Synovial Sarcoma1 trial

Lymphopenia1 trial

Non-small Cell Lung Cancer Stage IV1 trial

References

Drug Info

Quick Facts

Related News